GCP
ADMA icon

GSA Capital Partners’s ADMA Biologics ADMA Stock Holding History

GSA Capital Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Sell
16,076
-101,958
-86% -$929K 0.01% 1593
2026
Q1 		$1.06M Buy
+118,034
New +$1.86M 0.07% 461
2025
Q2 		– Sell
-18,464
Closed -$366K – 1704
2025
Q1 		$366K Buy
+18,464
New +$319K 0.03% 1015
2024
Q4 		– Sell
-35,313
Closed -$706K – 1564
2024
Q3 		$706K Sell
35,313
-109,045
-76% -$1.7M 0.05% 680
2024
Q2 		$1.61M Buy
144,358
+9,429
+7% +$79.1K 0.11% 239
2024
Q1 		$891K Buy
134,929
+118,215
+707% +$646K 0.07% 516
2023
Q4 		$76K Sell
16,714
-225,570
-93% -$835K 0.01% 1410
2023
Q3 		$867K Buy
242,284
+113,184
+88% +$436K 0.07% 478
2023
Q2 		$476K Buy
129,100
+61,626
+91% +$228K 0.05% 773
2023
Q1 		$223K Sell
67,474
-100,948
-60% -$349K 0.02% 1202
2022
Q4 		$653K Buy
+168,422
New +$520K 0.08% 435
2022
Q1 		– Sell
-96,578
Closed -$136K – 1363
2021
Q4 		$136K Sell
96,578
-508,659
-84% -$669K 0.02% 1283
2021
Q3 		$684K Sell
605,237
-255,674
-30% -$358K 0.07% 510
2021
Q2 		$1.38M Buy
860,911
+311,287
+57% +$548K 0.15% 141
2021
Q1 		$967K Buy
549,624
+222,572
+68% +$509K 0.16% 140
2020
Q4 		$638K Buy
327,052
+93,627
+40% +$197K 0.1% 287
2020
Q3 		$558K Buy
+233,425
New +$640K 0.09% 326
2020
Q2 		– Sell
-121,258
Closed -$349K – 583
2020
Q1 		$349K Buy
121,258
+75,174
+163% +$260K 0.09% 387
2019
Q4 		$184K Buy
+46,084
New +$201K 0.02% 1280

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GSA Capital Partners's ADMA Position: Q2 2026 in Review

GSA Capital Partners reduced its ADMA Biologics (ADMA) stake by 86% in Q2 2026, selling an estimated $929K and leaving 16,076 shares worth $135K. The position accounts for 0.01% of the portfolio, ranked #1593.

GSA Capital Partners first reported a position in ADMA in Q4 2019 and has held it in 19 quarters since. The position peaked at $1.61M in Q2 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • GSA Capital Partners held 16,076 shares of ADMA Biologics worth $135K as of Q2 2026.
  • GSA Capital Partners sold 101,958 ADMA Biologics shares in Q2 2026, an estimated $929K.
  • ADMA Biologics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1593 holding.
  • GSA Capital Partners first reported a position in ADMA Biologics in Q4 2019 and has held it in 19 quarters since.
  • GSA Capital Partners's ADMA Biologics position peaked at $1.61M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.